Changes to the Code
S. 2665 · Drug Shortage Prevention Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 356c Discontinuance or interruption in the production of life-saving drugs
5 changes the bill asks for here, 5 carried out
- Carried out:
in the section heading, by striking
Discontinuance or interruption in the production of life-saving drugs
and insertingNotification of issues affecting domestic supply of critical drugs
; - Carried out:
by striking subsections (a), (b), and (c), and inserting the following:
(a) Notification required.— (1) In general.— A manufacturer of a covered drug shall notify the Secretary, in accordance with subsection (b), of— (A) (i) a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to …
- Carried out:
in subsection (g), in the matter preceding paragraph (1), by striking
drug described in subsection (a)
and insertingcovered drug
; and - Carried out:
in subsection (j), by striking
drug described in subsection (a)
and insertingcovered drug
. - Carried out:
Paragraph (1) of section 506C(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356c(h)) is amended to read as follows:
(1) the term “covered drug” means a drug that is intended for human use and that— (A) is— (i) life-supporting; (ii) life-sustaining; or (iii) intended for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical …
§ 356c(a)–(e)
§ 356c. [struck: Discontinuance][inserted: Notification] [struck: or][inserted: of] [struck: interruption][inserted: issues] [struck: in][inserted: affecting] [struck: the][inserted: domestic] [struck: production][inserted: supply] of [struck: life-saving][inserted: critical] drugs
(a) [struck: In][inserted: Notification] [struck: general][inserted: required.—] [struck: A manufacturer of a drug—]
(1) [inserted: In general.—] [struck: that][inserted: A] [struck: is][inserted: manufacturer of a covered drug shall notify the Secretary, in accordance with subsection (b), of]—
(A)
(i) [inserted: a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to lead to a meaningful disruption in the supply of such drug in the United States;]
(ii) [inserted: a permanent discontinuance in the manufacture of an active pharmaceutical ingredient of such drug, or an interruption in the manufacture of an active pharmaceutical ingredient of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug; or]
(iii) [inserted: any other circumstance, such as an increase in demand or export restriction, that is likely to leave the manufacturer unable to meet demand for the drug without a meaningful shortfall or delay; and]
[struck: life-supporting;]
(B) [struck: life-sustaining;][inserted: the] [inserted: reasons for such discontinuance, interruption, ]or[inserted: other circumstance, if known.]
[struck: (C)] [struck: intended for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 247d of title 42; and]
(2) [inserted: Contents.—] [inserted: Notification under this subsection with respect to a covered drug shall include—]
(A) [inserted: with respect to the reasons for the discontinuation, interruption, or other circumstance described in paragraph (1)(A)(iii), if an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation, interruption, or other circumstance, the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known to the manufacturer;]
(B) [inserted: whether any associated device used for preparation or administration included in the drug is a reason for, or a risk factor in, such discontinuation, interruption, or other circumstance described in paragraph (1)(A)(iii);]
(C) [inserted: the expected duration of the interruption; and]
(D) [inserted: such other information as the Secretary may require.]
[struck: that is not a radio pharmaceutical drug product or any other product as designated by the Secretary,]
[struck: shall notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to lead to a meaningful disruption in the supply of that drug in the United States, or a permanent discontinuance in the manufacture of an active pharmaceutical ingredient or an interruption in the manufacture of the active pharmaceutical ingredient of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug, and the reasons for such discontinuance or interruption. Notification under this subsection shall include disclosure of reasons for the discontinuation or interruption, and if applicable, an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation or interruption, the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known by the manufacturer; whether any associated device used for preparation or administration included in the drug is a reason for, or a risk factor in, such discontinuation or interruption; the expected duration of the interruption; and such other information as the Secretary may require.]
(b) Timing[inserted: .—] A notice required under subsection (a) shall be submitted to the Secretary—
(1) at least 6 months prior to the date of the discontinuance or interruption;[struck: or]
(2) [struck: if][inserted: in] [struck: compliance][inserted: the] [inserted: case of such a notice ]with [struck: paragraph][inserted: respect] [struck: (1)][inserted: to] [struck: is][inserted: a] [struck: not][inserted: circumstance] [struck: possible][inserted: described in subsection (a)(1)(A)(iii)], as soon as practicable[struck: .][inserted: , or not later than 10 business days after the onset of the circumstance; or]
(3) [inserted: if compliance with paragraph (1) or (2) is not possible, as soon as practicable.]
(c) Distribution[inserted: .—] To the maximum extent practicable, the Secretary shall distribute, through such means as the Secretary [struck: deems][inserted: determines] appropriate, information on the discontinuance or interruption of the manufacture of[inserted: ,] [struck: the][inserted: or] [struck: drugs][inserted: other] [inserted: circumstance ]described in subsection (a)[inserted: (1)(A)(iii)] [inserted: that is likely ]to [inserted: lead to a shortage or meaningful disruption in the supply of, covered drugs to ]appropriate organizations, including physician, health provider, and patient organizations, as described in section [struck: 356e of this title][inserted: 506E].
(d) Confidentiality Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5 or section 1905 of title 18.
(e) Coordination with Attorney General Not later than 30 days after the receipt of a notification described in subsection (a), the Secretary shall—
§ 356c(f)–(h)
(e)(1)–(f)(2) unchanged ·
(3) not later than 45 calendar days after the issuance of a letter under paragraph (1), the Secretary shall make such letter and any response to such letter under paragraph (2) available to the public on the Internet Web site of the Food and Drug Administration, with appropriate redactions made to protect information described in subsection (d), except that, if the Secretary determines that the letter under paragraph (1) was issued in error or, after review of such response, the person had a reasonable basis for not notifying as required under subsection (a), the requirements of this paragraph shall not apply.
(g) Expedited inspections and reviews If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a drug shortage of a [struck: drug][inserted: covered] [struck: described in subsection (a)][inserted: drug], the Secretary shall, as appropriate—
(1) prioritize and expedite the review of a supplement to a new drug application submitted under section 355(b) of this title, an abbreviated new drug application submitted under section 355(j) of this title, or a supplement to such an application submitted under section 355(j) of this title, that could help mitigate or prevent such shortage; or
(2) prioritize and expedite an inspection or reinspection of an establishment that could help mitigate or prevent such drug shortage.
(h) Definitions For purposes of this section—
(1) the term “[inserted: covered ]drug”[inserted: means a drug that is intended for human use and that]—
(A) [inserted: is—]
(i) [inserted: life-supporting;]
(ii) [inserted: life-sustaining; or]
(iii) [inserted: intended for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 319 of the Public Health Service Act;]
[struck: means a drug (as defined in section 321(g) of this title) that is intended for human use and that is subject to section 353(b)(1) of this title; and]
(B) [struck: does][inserted: is] not [struck: include][inserted: a] [struck: biological][inserted: radio] [struck: products][inserted: pharmaceutical] [struck: (as][inserted: drug] [struck: defined][inserted: product] [struck: in][inserted: or] [struck: section][inserted: any] [struck: 262][inserted: other] [struck: of][inserted: product] [struck: title][inserted: as] [struck: 42),][inserted: designated] [struck: unless otherwise provided ]by the Secretary[struck: in the regulations promulgated under subsection (i)];[inserted: and]
(C) [inserted: is not a biological product (as defined in section 351(i) of the Public Health Service Act), unless otherwise provided by the Secretary in the regulations promulgated under subsection (i);]
(2) the term “drug shortage” or “shortage”, with respect to a drug, means a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug; and
(3) the term “meaningful disruption”—
§ 356c(i)–(j)
(h)(3)(A)–(i)(4)(C) unchanged ·
(5) Restrictions Notwithstanding any other provision of Federal law, in implementing this section, the Secretary shall only promulgate regulations as described in paragraph (4).
(j) Risk management plans Each manufacturer of a [inserted: covered ]drug [struck: described in subsection (a) ]or of any active pharmaceutical ingredient or any associated medical device used for preparation or administration included in the drug, shall develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which such drug or active pharmaceutical ingredient of such drug is manufactured. A risk management plan under this section shall be subject to inspection and copying by the Secretary pursuant to an inspection or a request under section 374(a)(4) of this title.
21 U.S.C. § 360 Registration of producers of drugs or devices
3 changes the bill asks for here, 2 carried out
- Carried out:
by striking
annually to the Secretary
in the first sentence and insertingto the Secretary, once during the month of March each year and once during the month of September each year,
; - Not carried out:
by inserting
, and the legal names of, and any additional information the Secretary may require, regarding suppliers of active pharmaceutical ingredients and intermediate and in-process materials such person used for the manufacture, preparation, propagation, compounding, or processing of such drug, and the amount of such drug manufactured, prepared, propagated, compounded, or processed using each such active pharmaceutical ingredient or intermediate or in-process material sourced from each such supplier
before the period at the end of the first sentence; andWe can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: inserting QTEXT before the period at the end of the first sentence; and - Carried out:
by inserting after the first sentence the following:
In addition to the reporting required under the preceding sentence, each person who registers with the Secretary under this section with regard to a drug may voluntarily report on the information described in the preceding sentence, at such other times as the Secretary may specify.
.
§ 360(j)Filing of lists of drugs and devices manufactured, prepared, propagated and compounded by registrants; statements; accompanying disclosures(2)–(4)
Start of § 360 to (j)(2)(C) unchanged ·
(D) Any material change in any information previously submitted pursuant to this paragraph or paragraph (1).
(3)
(A) Each person who registers with the Secretary under this section with regard to a drug shall report [struck: annually ]to the Secretary[inserted: ,] [inserted: once during the month of March each year and once during the month of September each year, ]on the amount of each drug listed under paragraph (1) that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution. [inserted: In addition to the reporting required under the preceding sentence, each person who registers with the Secretary under this section with regard to a drug may voluntarily report on the information described in the preceding sentence, at such other times as the Secretary may specify. ]Such information may be required to be submitted in an electronic format as determined by the Secretary. The Secretary may require that information required to be reported under this paragraph be submitted at the time a public health emergency is declared by the Secretary under section 247d of title 42.
(B) By order of the Secretary, certain biological products or categories of biological products regulated under section 262 of title 42 may be exempt from some or all of the reporting requirements under subparagraph (A), if the Secretary determines that applying such reporting requirements to such biological products or categories of biological products is not necessary to protect the public health.
(4) The Secretary may also require each registrant under this section to submit a list of each drug product which (A) the registrant is manufacturing, preparing, propagating, compounding, or processing for commercial distribution, and (B) contains a particular ingredient. The Secretary may not require the submission of such a list unless he has made a finding that the submission of such a list is necessary to carry out the purposes of this chapter.
Rest of § 360 unchanged ·